Contact Information: For More Information, Contact: James E. Fickenscher CFO Auxilium Pharmaceuticals, Inc. (484) 321-5900 William Q. Sargent, Jr. V.P., IR Auxilium Pharmaceuticals, Inc. (484) 321-5900
Auxilium Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - August 27, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that executive management will participate in the Thomas
Weisel Partners Healthcare Conference to be held September 9 - 11, 2009 at
the Four Seasons Hotel in Boston. Mr. Armando Anido, Chief Executive
Officer, is scheduled to present an overview of the Company and its product
pipeline at 10:55 a.m. EDT on Wednesday, September 9, 2009.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has five
projects in clinical development. XIAFLEX™ (clostridial collagenase for
injection), formerly referred to as AA4500, has completed phase III
clinical trials for the treatment of Dupuytren's contracture, is in phase
IIb of development for the treatment of Peyronie's disease and is in phase
II of development for treatment of Frozen Shoulder syndrome (Adhesive
Capsulitis). Auxilium's transmucosal film product candidate for the
treatment of overactive bladder (AA4010) is in phase I of development.
Auxilium also has one pain product (fentanyl) using its transmucosal film
delivery system in phase I of development. Auxilium has rights to
additional pain products and products for hormone replacement and urologic
disease using its transmucosal film delivery system. The Company is
currently seeking a partner to further develop these transmucosal film
product candidates. Auxilium also has options to all indications using
XIAFLEX for non-topical formulations. For additional information, visit
http://www.auxilium.com.
Safe Harbor Statement
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Thomas Weisel Partners
Healthcare Conference, and products in development for the treatment of
Dupuytren's contracture, Peyronie's disease and Frozen Shoulder Syndrome
and for pain, hormone replacement and urologic disease. All statements
other than statements of historical facts contained in this release,
including but not limited to, statements regarding future expectations,
plans and prospects for the Company, statements regarding forward-looking
financial information and other statements containing the words "believe,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and similar expressions, as they relate to the
Company, constitute forward-looking statements. Actual results may differ
materially from those reflected in these forward-looking statements due to
various factors, including further evaluation of clinical data, results of
clinical trials, decisions by regulatory authorities as to whether and when
to approve drug applications, and general financial, economic, regulatory
and political conditions affecting the biotechnology and pharmaceutical
industries and those discussed in the Company's Annual Report on Form 10-K
for the year ended December 31, 2008 and the Company's Quarterly Report on
Form 10-Q for the period ended June 30, 2009 under the heading "Risk
Factors," which are on file with the Securities and Exchange Commission
(the "SEC") and may be accessed electronically by means of the SEC's home
page on the Internet at http://www.sec.gov or by means of Auxilium's home
page on the Internet at http://www.Auxilium.com under the heading "Investor
Relations -- SEC Filings." There may be additional risks that Auxilium does
not presently know or that Auxilium currently believes are immaterial which
could also cause actual results to differ from those contained in the
forward-looking statements. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect. Therefore,
you should not rely on any such factors or forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.